EP CVD drive fails to address drug rationing

22 July 2007

The European Parliament has called on the European Union's member states and the European Commission to tackle cardiovascular disease (CVD), the region's biggest killer. However, Members of the European Parliament focused on prevention strategies, public awareness campaigns and the promotion of healthy lifestyles over treatment, including drugs.

However, a European free-market think-tank, the Stockholm Network, repeated a call to action to address what it termed "the growing burden of high cholesterol." Last year, the group published a report calling for European governments to give greater priority to cholesterol lowering which, the SN argues, involves the promotion of statins (Marketletter April 10, 2006).

Crisis unresolved while drugs rationed

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight